Search Press releases

5 Aug 2024

UCB announces European Commission approval for 320 mg device presentations of BIMZELX[®]▼(bimekizumab)

Read More
25 Jul 2024

Strong Start into UCB’s Decade of Growth

Read More
28 Jun 2024

Acquisition of own shares

Read More
28 Jun 2024

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

Read More
26 Jun 2024

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

Read More
14 Jun 2024

Acquisition of own shares

Read More

Stay up-to-date on the latest news and information from UCB